DBV Technologies grants CEO Daniel Tassé 1,740,000 performance share units tied to FDA milestones

• DBV Technologies adopted 2026 Performance Share Unit Plan, granting CEO Daniel Tassé 1,740,000 performance share units with grant date May 5, 2026.
• Vesting hinges on FDA acceptance for review of Viaskin Peanut biologics license applications, split evenly between ages 4-7 and ages 1-3; a single FDA acceptance covering both age groups triggers full eligibility.
• Unmet performance conditions by July 1, 2028 result in forfeiture; earned shares deliver in four 25% installments on July 1, 2028, Jan. 1, 2029, July 1, 2029, Jan. 1, 2030.
• A Change in Control deems performance conditions achieved, leaving continued employment as remaining vesting requirement; board can substitute cash of equivalent value if CEO is not a French tax resident at delivery.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. DBV Technologies SA published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-206315), on May 05, 2026, and is solely responsible for the information contained therein.